FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:185-187 January 11, 2007 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Motzer, R. J. Related Article by Escudier, B. PubMed Citation

Renal-cell carcinoma is among the most resistant of tumors to therapy. Until 2005, only a single treatment, high-dose interleukin-2, had been approved by the Food and Drug Administration (FDA) for the treatment of this disease. The approval was based on durable complete responses in 5% of patients with metastatic disease,¹ but high-dose therapy with interleukin-2 is quite toxic, and in most patients its benefit is unclear.

In this issue of the Journal, Motzer et al.² and Escudier et al.³ report on the results of phase 3 trials of two oral, small-molecule kinase inhibitors, sunitinib malate and sorafenib, respectively. Both drugs . . . [Full Text of this Article]

Source Information

From the Division of Hematology–Oncology and the Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas.

This article has been cited by other articles:

• Brugarolas, J., Lotan, Y., Watumull, L., Kabbani, W. (2008). Sirolimus in Metatastic Renal Cell Carcinoma. JCO 26: 3457-3460 [Full Text]  
• Signoretti, S., Bratslavsky, G., Waldman, F. M., Reuter, V. E., Haaga, J., Merino, M., Thomas, G. V., Pins, M. R., Libermann, T., Gillespie, J., Tomaszewski, J. E., Compton, C. C., Hruszkewycz, A., Linehan, W. M., Atkins, M. B. (2008). Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. Clin. Cancer Res. 14: 3699-3705 [Abstract] [Full Text]  
• Hipp, M. M., Hilf, N., Walter, S., Werth, D., Brauer, K. M., Radsak, M. P., Weinschenk, T., Singh-Jasuja, H., Brossart, P. (2008). Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 111: 5610-5620 [Abstract] [Full Text]  
• van der Veldt, A. A.M., Meijerink, M. R., van den Eertwegh, A. J.M., Bex, A., de Gast, G., Haanen, J. B.A.G., Boven, E. (2008). Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor Response. Clin. Cancer Res. 14: 2431-2436 [Abstract] [Full Text]  
• Waxman, J., Kenny, L., Ngan, S. (2008). New treatments for kidney cancer. BMJ 336: 681-682 [Full Text]  
• Blish, K. R., Wang, W., Willingham, M. C., Du, W., Birse, C. E., Krishnan, S. R., Brown, J. C., Hawkins, G. A., Garvin, A. J., D'Agostino, R. B. Jr., Torti, F. M., Torti, S. V. (2008). A Human Bone Morphogenetic Protein Antagonist Is Down-Regulated in Renal Cancer. Mol. Biol. Cell 19: 457-464 [Abstract] [Full Text]  
• Annas, G. J. (2007). Cancer and the Constitution -- Choice at Life's End. NEJM 357: 408-413 [Full Text]  
• (2007). Sunitinib vs. Interferon-{alpha} in Patients with Metastatic Renal Carcinoma. JWatch Oncology and Hematology 2007: 2-2 [Full Text]